Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.26USD
4:00pm EDT
Change (% chg)

$-0.14 (-4.12%)
Prev Close
$3.40
Open
$3.38
Day's High
$3.42
Day's Low
$3.22
Volume
125,020
Avg. Vol
161,352
52-wk High
$4.51
52-wk Low
$2.09

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $348.83
Shares Outstanding(Mil.): 102.60
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -0.21 -- --
ROI: -34.13 -7.30 12.79
ROE: -34.39 -10.05 14.67

BRIEF-Catalyst Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis

* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:

Apr 19 2018

BRIEF-Catalyst Pharma Submits NDA For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME

Mar 29 2018

BRIEF-Catalyst Pharmaceuticals Announces Q4 Gaap Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 14 2018

BRIEF-Catalyst Pharmaceuticals Announces Plans To Resubmit New Drug Application For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES PLANS TO RESUBMIT NEW DRUG APPLICATION FOR FIRDAPSE®

Feb 12 2018

BRIEF-Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma

* GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING Source text for Eikon: (http://bit.ly/2jaVqTo) Further company coverage:

Dec 08 2017

BRIEF-Catalyst Pharmaceuticals Inc Prices Previously Announced Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. PRICES PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF COMMON STOCK

Nov 28 2017

BRIEF-Catalyst Pharma Announces Proposed Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Nov 27 2017

BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME

Nov 27 2017

Earnings vs. Estimates